Δημοσίευση

Pain palliative therapy in women with breast cancer osseous metastatic disease and the role of specific serum cytokines as prognostic factors.

ΤίτλοςPain palliative therapy in women with breast cancer osseous metastatic disease and the role of specific serum cytokines as prognostic factors.
Publication TypeJournal Article
Year of Publication2014
AuthorsIakovou, I., Doumas A., Badiavas K., Mpalaris V., Frangos S., & Farmakis G.
JournalCancer Biother Radiopharm
Volume29
Issue3
Pagination116-23
Date Published2014 Apr
ISSN1557-8852
Λέξεις κλειδιάAged, Bone Neoplasms, Breast Neoplasms, Cytokines, Female, Humans, Interleukin-6, Middle Aged, Organometallic Compounds, Organophosphorus Compounds, Pain, Intractable, Palliative Care, Prognosis, Prospective Studies, Radiopharmaceuticals, Rhenium, Strontium Radioisotopes
Abstract

PURPOSE: To evaluate the efficacy of radionuclide palliative therapy (RPT) in women suffering from painful metastatic bone disease (MBD) due to breast cancer (BrCa), and to investigate the possible relationship between the RPT efficacy and cytokines levels.METHODS: Sixty-three BrCa women patients with MBD enrolled in a prospective, nonrandomized study. Thirty were treated with Rhenium-186-hydroxyethylidenediphosphonic acid ((186)Re-HEDP), 21 with Strontium-89-Chloride ((89)Sr-Cl2), and 12 with Samarium-153-thylenediaminetetramethylenephosphonic acid ((153)Sm-EDTMP). Blood samples were collected pre- and post-therapy to assess the interleukin (IL)-2, IL-6 and tumor necrosis factor (TNF)-a titers. The palliative effect of the treatment was evaluated using a modified Wisconsin test.RESULTS: All three radiopharmaceuticals were equally effective in pain relief. Pain palliation was complete in 52% of patients, partial in 31%, and absent in 16%. Responders to therapy had higher IL-2 and lower IL-6/TNF-a concentrations, compared with nonresponders, even though statistically significant difference in cytokines levels between responders and nonresponders before treatment was noted only for IL-6.CONCLUSION: All used radiopharmaceuticals had the same therapeutic effect. Pretherapy low titers of IL-6 levels seems to have a favorable prognostic value for the therapeutic outcome, while IL-2 and TNF-a alterations pre- and post-therapy can only serve as markers of a better RPT response.

DOI10.1089/cbr.2013.1551
Alternate JournalCancer Biother Radiopharm
PubMed ID24392878

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.